Clinical trials: Erythropoietin
Anemia, Neoplasms
A Study to Assess the Response Rate of PROCRIT (Epoetin Alfa) Given at a Dose of 40,000 Units Once a Week to Cancer Patients With Anemia Who Are Not Receiving Chemotherapy.
The purpose of this study is to evaluate the effectiveness and safety of PROCRIT (Epoetin alfa) administered at 40,000 Units weekly in cancer patients that are not receiving chemotherapy or radiation therapy.
- Trial name
- NCT00350090
- Testing
- Epoetin Alfa
- Volunteers
- 98 people
- Sponsor
- Ortho Biotech Products, L.P.
Anemia, Leukemia, Lymphocytic, Chronic
Epoetin Alfa for the Treatment of Anemia Resulting From Chronic Lymphocytic Leukemia
The purpose of this study is to evaluate the effect of treatment with epoetin alfa versus placebo on the percentage of red blood cells in anemic patients with chronic lymphocytic (white blood cell) leukemia and its effect on the…
- Conditions
- Anemia, Leukemia, Lymphocytic, Chronic, Leukemia, Lymphocytic, Cancer
- Trial name
- NCT00270049
- Testing
- epoetin alfa
- Volunteers
- 195 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Anemia
Treatment of Anemia in Diabetic Subjects With CKD
The purpose of this study is to compare the proportion of subjects receiving either Epoetin alfa (PROCRIT®) or placebo who are able to achieve a hemoglobin response, defined by at least a 1 gram/deciliter increase from baseline…
- Trial name
- NCT00240734
- Testing
- Epoetin alfa
- Volunteers
- 11 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Complication of Renal Dialysis
Atorvastatin Reduces Chronic Inflammation and aVerage Epogen Dose (ARChIVED)
The specific aim of this trial is to determine whether initiating moderate- or high-intensity atorvastatin therapy in hemodialysis patient not previously on a statin reduces inflammation and lowers average Epogen utilization.
- Trial name
- ARChIVED (NCT02764736)
- Testing
- Atorvastatin
- Sponsor
- Albert Einstein Healthcare Network
Anemia of Chronic Kidney Disease
Study of HEMAX PFS Versus EPREX/ ERYPO® in Predialysis Chronic Kidney Disease
Phase III, multicenter, randomized, open, controlled clinical trial. A study designed as phase III, in 120 patients with chronic renal failure in the pre-dialysis stage, evaluate efficacy and safety of Hemax PFS® (PFS: prefilled…
- Trial name
- NCT04036253
- Testing
- Erythropoietin alfa
- Where
- 11 sites in Argentina, Paraguay
- Volunteers
- 43 people
- Sponsor
- Bio Sidus SA
Blood Transfusion, Blood Transfusion, Autologous
A Study to Determine the Effectiveness of Epoetin Alfa in Facilitating Self-donation of Blood Before Surgery in Non-anemic Patients Who Are Undergoing Orthopedic, Heart and Blood Vessel, or Breast Reduction Surgery; Performed in Combination With a Procedure to Reduce Blood Loss During Surgery.
The purpose of this study is to determine the safety and effectiveness of epoetin alfa and whether epoetin alfa will enable self-donation of blood during an 11-day period before surgery (which is shorter than the conventional…
- Conditions
- Blood Transfusion, Blood Transfusion, Autologous, Orthopedic Procedures, Orthopedic Surgery
- Trial name
- NCT00270023
- Testing
- epoetin alfa
- Volunteers
- 112 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Anemia, Chronic Renal Failure
Safety & Efficacy of Peginesatide for Treatment of Anemia in Participants on Dialysis Not Receiving an ESA
The purpose of this study is to evaluate the safety and efficacy of peginesatide for the treatment of anemia in participants with chronic kidney disease who are on dialysis and are not taking any treatment to increase their red…
- Conditions
- Anemia, Chronic Renal Failure, Chronic Kidney Disease
- Trial name
- NCT00680043
- Testing
- peginesatide, Epoetin Alfa
- Where
- 11 sites in Russia
- Volunteers
- 114 people
- Sponsor
- Affymax
Anemia, Leukemia
Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer
RATIONALE: Epoetin alfa and epoetin beta may cause the body to make more red blood cells. Red blood cells contain iron that is needed to carry oxygen to the tissues.
- Conditions
- Anemia, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00482716
- Testing
- epoetin alfa, epoetin beta, iron dextran complex
- Where
- United Kingdom
- Volunteers
- 80 people
- Sponsor
- St. Bartholomew's Hospital
Anemia of End Stage Renal Disease
Comparison Among Erythropoietin Stimulating Agents
Background: Despite extensive use, to the best of our knowledge, no trial has simultaneously compared the three currently used erythropoietin stimulating agents (ESAs) in a prospective manner, in treatment of anemia of end stage…
- Trial name
- NCT02049346
- Testing
- Epoetin alpha or beta (Epoetin group), Darbepoetin alfa, Methoxy polyethylene glycol-epoetin beta
- Where
- Qatar
- Volunteers
- 327 people
- Sponsor
- Hamad Medical Corporation
Chronic Kidney Disease, End-stage Renal Disease
MONITOR-CKD5 - Multi-level Evaluation of Anaemia Treatment, Outcomes, and Determinants in Chronic Kidney Disease Stage 5
MONITOR-CKD5 is an observational, pharmaco-epidemiological study to evaluate the multi-level factors and outcomes associated with the treatment of renal anaemia with biosimilar epoetin alfa in Stage 5 CKD patients requiring…
- Conditions
- Chronic Kidney Disease, End-stage Renal Disease, Anaemia
- Trial name
- MONITOR-CKD5 (NCT01121237)
- Testing
- Recombinant human erythropoietin alfa (biosimilar)
- Where
- 95 sites in Austria, France and 8 more
- Volunteers
- 2,086 people
- Sponsor
- Sandoz
Bio-Equivalency of 2 Treatment Schedules in HD Patients
Anaemia Correction in Haemodialyzed Patients - Comparative Analysis of Two Erythropoietin Stimulating Agents Schedules
Several recent reports support the efficacy of once every-other-week epoetinum administration in the maintenance phase of the anaemia treatment in predialysis, haemodialysis and in peritoneal dialysis CKD patients.
- Trial name
- VAES (NCT00551603)
- Testing
- switch (epoetinum beta, darbepoetinum), continuation (darbepoetinum)
- Where
- 2 sites in Romania
- Sponsor
- Anemia Working Group Romania
Kidney Failure, Renal Failure
Erythropoietin (EPO) to Protect Renal Function After Cardiac Surgery
The purpose of this study is to evaluate the potential of erythropoietin in reducing risk and degree of acute kidney injury after cardiac surgery.
- Trial name
- EPRICS (NCT01423955)
- Testing
- Erythropoietin zeta
- Where
- Sweden
- Volunteers
- 75 people
- Sponsor
- Region Skane
End Stage Renal Failure, Anaemia
Effectiveness of a Biosimilar Epoetin Alfa in Stable 'End Stage Renal Failure'
This is a prospective, observational, non-inferior study in ESRF patients stable on Eprex who are switched to a Biosimilar Epoetin Alfa. Study plans to recrut 44 patients.
- Trial name
- NCT02341547
- Testing
- a Biosimilar Epoetin Alfa
- Volunteers
- 44 people
- Sponsor
- Penang Hospital, Malaysia
Anemia
A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors
This study will evaluate the safety of subcutaneous (SC) epoetin beta (NeoRecormon) in adults with solid tumors being treated with platinum-based chemotherapy capable of inducing anemia.
- Trial name
- NCT02554942
- Testing
- Epoetin beta
- Where
- 13 sites in Spain
- Volunteers
- 28 people
- Sponsor
- Hoffmann-La Roche
Extreme Prematurity
Preterm Erythropoietin Neuroprotection Trial (PENUT Trial)
Recombinant human erythropoietin (Epo) is a promising novel neuroprotective agent. Epo decreases neuronal programmed cell death resulting from brain injury; it has anti-inflammatory effects, increases neurogenesis, and protects…
- Trial name
- PENUT (NCT01378273)
- Testing
- Epo, Control
- Where
- 19 sites in United States
- Volunteers
- 941 people
- Sponsor
- University of Washington
Stroke
REGENESIS (US): A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients
To assess the safety and tolerability of NTx™-265 when given to acute ischemic stroke patients. To assess the neurological outcome in acute ischemic stroke patients treated with NTx™-265, when compared with patients given a…
- Trial name
- REGENESIS (NCT00715364)
- Testing
- NTx™-265: rhCG, then rEPO
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Stem Cell Therapeutics Corp.
Anemia
Study of the Safety and Efficacy of Ferrlecit® Maintenance Dosing in Pediatric Hemodialysis Patients
A phase 4 clinical investigation in iron-replete pediatric hemodialysis patients, whose legal guardian had provided signed informed consent, and who had satisfied the inclusion and exclusion criteria of the study.
- Trial name
- NCT00224003
- Testing
- Sodium Ferric Gluconate Complex in Sucrose.
- Where
- 10 sites in United States
- Volunteers
- 23 people
- Sponsor
- Watson Pharmaceuticals
Erythropoietin Resistant Anemia (EPO Resistant Anemia)
Prevalence of Erythropoiesis Stimulating Agents Hyporesponsiveness in Dialysis Patients in Assiut University Hospital
The prevalence of erthropoietin stimulating agents hyporesponsiveness in hemodialysis patients in Assiut university hospital Assessment of cardiovascular diseases risk in patients with erythropoiesis stimulating agents…
- Trial name
- NCT06053866
- Volunteers
- 240 people
- Sponsor
- Assiut University
Comatose Survivors of Cardiac Arrest
High Dose of Erythropoietin Analogue After Cardiac Arrest
The investigators hypothesised that the neuroprotective effects of erythropoietin and its analogues could lead to an improve outcome after cardiac arrest.
- Trial name
- Epo-ACR-02 (NCT00999583)
- Testing
- EPOETINE ALPHA, Control arm
- Where
- France
- Volunteers
- 500 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Anemia
Treatment of Chronic Anemia With Epoetin Alfa in Elderly
The purpose of this study is to determine if chronic anemia can be corrected with epoetin alfa and does the subsequent correction lead to an improvement in fatigue,quality of life or mobility among elderly.
- Trial name
- NCT00337441
- Testing
- Epoetin Alfa (drug)
- Where
- 2 sites in United States
- Volunteers
- 62 people
- Sponsor
- Research and Education Foundation of Michael Reese Hospital